Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer
Background: Quantification of the magnitude of thrombotic risk associated with malignancy and with anti-cancer therapy is indispensable to use anticoagulant drugs which selectively interfere with haemostatic mechanisms protecting patients from venous thromboembolism (VTE) and probably from tumor pro...
Збережено в:
| Дата: | 2007 |
|---|---|
| Автори: | , , , , , , , , , , , , , |
| Формат: | Стаття |
| Мова: | English |
| Опубліковано: |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
2007
|
| Назва видання: | Experimental Oncology |
| Теми: | |
| Онлайн доступ: | http://dspace.nbuv.gov.ua/handle/123456789/138581 |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|
| Назва журналу: | Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| Цитувати: | Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer / M.L. Papa, F. Capasso, L. Pudore, S. Torre, S. Mango, V. Russo, P. Delrio, R. Palaia, F. Ruffolo, M.D. d’Eufemia, D. De Lucia, M. Napolitano, P. Di Micco, V. Parisi // Experimental Oncology. — 2007. — Т. 29, № 2. — С. 111-115. — Бібліогр.: 26 назв. — англ. |
Репозиторії
Digital Library of Periodicals of National Academy of Sciences of Ukraine| id |
irk-123456789-138581 |
|---|---|
| record_format |
dspace |
| institution |
Digital Library of Periodicals of National Academy of Sciences of Ukraine |
| collection |
DSpace DC |
| language |
English |
| topic |
Original contributions Original contributions |
| spellingShingle |
Original contributions Original contributions Papa, M.L. Capasso, F. Pudore, L. Torre, S. Mango, S. Russo, V. Delrio, P. Palaia, R. Ruffolo, F. d’Eufemia, M.D. De Lucia, D. Napolitano, M. Di Micco, P. Parisi, V. Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer Experimental Oncology |
| description |
Background: Quantification of the magnitude of thrombotic risk associated with malignancy and with anti-cancer therapy is indispensable to use anticoagulant drugs which selectively interfere with haemostatic mechanisms protecting patients from venous thromboembolism (VTE) and probably from tumor progression. However, none of activation coagulation markers has any predictive value for the occurrence of the thrombotic events in one individual patient. Current clotting methods can’t reveal the overall dynamic clot formation; in contrast thromboelastographic methods specifically assess overall coagulation kinetics and its strength in whole blood. Aim: Objective of study was to evaluate if the activation of coagulation as eventually revealed by ROTEM® thromboelastometry could assess an hypercoagulable state in surgical neoplastic patients. Patients and Methods: Fifty consecutive patients with carcinoma of the digestive tract in preoperative period (23 M, 27 F aging 61.5 (45–79 years) and 147 healthy subjects (71 M, 76 F) were studied. A recent thromboelastometric method based on thrombelastography after Hartert was employed. Measurements were performed on ROTEM Coagulation Analyzer. The continuous coagulation data from 50 min course were transformed into dynamic velocity profiles of WB clot formation. Results: Standard parameters (CT, CFT, MCF) of cancer patients were similar to controls. CT (in cancer patients): females 50 s (38.3–58.7), males 50 s (42–71.2) vs 51 s (42–59), p = 0.1210 / 53 s (42–74.8), p = 0.1975 (in controls). CFT (in cancer patients): females 72 s (32- 92.4), males 80 s (50.2- 128.7) vs 78 s (62–100), p = 0.0128 / 80 s (59–124.4), p = 0.9384 (in controls). MCF (in cancer patients): females 70 mm (59.9–82.5), males 63 mm (56–73.7) vs 69 mm (59–95.8), p = 0.9911 / 69 mm (53.6–90), p = 0.0135 (in controls). Females showed a higher MaxVel when compared to males. The MaxVel was increased in cancer patients: females 19 mm /100 s (14.3–49.5) males 18 mm / 100 s (11–27) vs 15 mm 100 s (11.8–22), p < 0.001 / 13 mm / 100 s (10–21.8), p < 0.001 in controls .The t-MaxVel was shortened in cancer patients: females 65 s (48.6–112.8), males 81 s (50.1–135.9) vs 115 s (56.8–166), p <0.001 / 115 s (59.8–180.8), p = 0.0002 in controls. The AUC was increased in cancer patients: females 6451 mm 100 (5511–8148), males 5984 mm 100 (5119-6899) vs 5778 mm 100 (4998–6655), p < 0.001 / 5662 mm 100 (4704–6385), p = 0.0105. Conclusion: Unlike other assays measuring variations in a single component during coagulation, the thrombelastographic method records a profile of real-time continuous WB clot formation, and may provide extensive informations on haemostasis in neoplastic patients before surgery. |
| format |
Article |
| author |
Papa, M.L. Capasso, F. Pudore, L. Torre, S. Mango, S. Russo, V. Delrio, P. Palaia, R. Ruffolo, F. d’Eufemia, M.D. De Lucia, D. Napolitano, M. Di Micco, P. Parisi, V. |
| author_facet |
Papa, M.L. Capasso, F. Pudore, L. Torre, S. Mango, S. Russo, V. Delrio, P. Palaia, R. Ruffolo, F. d’Eufemia, M.D. De Lucia, D. Napolitano, M. Di Micco, P. Parisi, V. |
| author_sort |
Papa, M.L. |
| title |
Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer |
| title_short |
Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer |
| title_full |
Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer |
| title_fullStr |
Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer |
| title_full_unstemmed |
Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer |
| title_sort |
thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer |
| publisher |
Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |
| publishDate |
2007 |
| topic_facet |
Original contributions |
| url |
http://dspace.nbuv.gov.ua/handle/123456789/138581 |
| citation_txt |
Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer / M.L. Papa, F. Capasso, L. Pudore, S. Torre, S. Mango, V. Russo, P. Delrio, R. Palaia, F. Ruffolo, M.D. d’Eufemia, D. De Lucia, M. Napolitano, P. Di Micco, V. Parisi // Experimental Oncology. — 2007. — Т. 29, № 2. — С. 111-115. — Бібліогр.: 26 назв. — англ. |
| series |
Experimental Oncology |
| work_keys_str_mv |
AT papaml thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT capassof thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT pudorel thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT torres thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT mangos thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT russov thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT delriop thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT palaiar thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT ruffolof thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT deufemiamd thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT deluciad thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT napolitanom thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT dimiccop thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer AT parisiv thromboelastographicprofilesasatoolforthromboticriskindigestivetractcancer |
| first_indexed |
2023-10-18T21:19:12Z |
| last_indexed |
2023-10-18T21:19:12Z |
| _version_ |
1796152498042437632 |
| spelling |
irk-123456789-1385812018-06-20T03:03:21Z Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer Papa, M.L. Capasso, F. Pudore, L. Torre, S. Mango, S. Russo, V. Delrio, P. Palaia, R. Ruffolo, F. d’Eufemia, M.D. De Lucia, D. Napolitano, M. Di Micco, P. Parisi, V. Original contributions Background: Quantification of the magnitude of thrombotic risk associated with malignancy and with anti-cancer therapy is indispensable to use anticoagulant drugs which selectively interfere with haemostatic mechanisms protecting patients from venous thromboembolism (VTE) and probably from tumor progression. However, none of activation coagulation markers has any predictive value for the occurrence of the thrombotic events in one individual patient. Current clotting methods can’t reveal the overall dynamic clot formation; in contrast thromboelastographic methods specifically assess overall coagulation kinetics and its strength in whole blood. Aim: Objective of study was to evaluate if the activation of coagulation as eventually revealed by ROTEM® thromboelastometry could assess an hypercoagulable state in surgical neoplastic patients. Patients and Methods: Fifty consecutive patients with carcinoma of the digestive tract in preoperative period (23 M, 27 F aging 61.5 (45–79 years) and 147 healthy subjects (71 M, 76 F) were studied. A recent thromboelastometric method based on thrombelastography after Hartert was employed. Measurements were performed on ROTEM Coagulation Analyzer. The continuous coagulation data from 50 min course were transformed into dynamic velocity profiles of WB clot formation. Results: Standard parameters (CT, CFT, MCF) of cancer patients were similar to controls. CT (in cancer patients): females 50 s (38.3–58.7), males 50 s (42–71.2) vs 51 s (42–59), p = 0.1210 / 53 s (42–74.8), p = 0.1975 (in controls). CFT (in cancer patients): females 72 s (32- 92.4), males 80 s (50.2- 128.7) vs 78 s (62–100), p = 0.0128 / 80 s (59–124.4), p = 0.9384 (in controls). MCF (in cancer patients): females 70 mm (59.9–82.5), males 63 mm (56–73.7) vs 69 mm (59–95.8), p = 0.9911 / 69 mm (53.6–90), p = 0.0135 (in controls). Females showed a higher MaxVel when compared to males. The MaxVel was increased in cancer patients: females 19 mm /100 s (14.3–49.5) males 18 mm / 100 s (11–27) vs 15 mm 100 s (11.8–22), p < 0.001 / 13 mm / 100 s (10–21.8), p < 0.001 in controls .The t-MaxVel was shortened in cancer patients: females 65 s (48.6–112.8), males 81 s (50.1–135.9) vs 115 s (56.8–166), p <0.001 / 115 s (59.8–180.8), p = 0.0002 in controls. The AUC was increased in cancer patients: females 6451 mm 100 (5511–8148), males 5984 mm 100 (5119-6899) vs 5778 mm 100 (4998–6655), p < 0.001 / 5662 mm 100 (4704–6385), p = 0.0105. Conclusion: Unlike other assays measuring variations in a single component during coagulation, the thrombelastographic method records a profile of real-time continuous WB clot formation, and may provide extensive informations on haemostasis in neoplastic patients before surgery. Предпосылки исследования количественная оценка риска тромбоза, связанного со злокачественными заболеваниями и противоопухолевой терапией, обязательно включает в себя применение средств-антикоагулянтов, защищающих больного от развития венозной тромбоэмболии (VTE)и возможно п рогрессии заболевания . Тем не менее ни один из маркеров ак- тивации коагуляции не имеет прогностической ценности с точки зрения возможности возникновения тромбоза у каждого отдельно взятого пациента. Современные мето ды оценки свертывания крови не отража ют образование тромба винамике ; наоборот, метод тромбо эластографии дает возможность специфически оценить кинетику свертывания крови целом . Цель: определить, в какой мере активность коагуляции, определяемой методом тромбоэ ластометрии, отражает состояние гиперсвертываемости крови у больных онкологического профиля после хирургического вмешательства. Пациенты и м ды: обследованы 50 больных раком пищ еваритель ного тракта в дооп ерационный п ериод (27 женщин, 23 му жчины, средний возраст 61,5 года (45–79 лет) и 147 здоровых доноров (71 мужчина, 76 женщин). Применяли метод тромбоэластометрии , основанный на тромбоэластографии Гартерта, с использованием анализатора коагуляциифирмыROTEM. Текущие д анные о свертывании за 50 мин измерений представили в виде динамичных профилей вязкости при образовании сгустка крови. Результаты: стандартные параметры (перио д коагуляции (CT), перио д образования сгу стка (CFT), максимал ь ная п лот- ность сгустка (MCF)) больных онкологического п рофиля близки к контроль ным . CT у больных онкологического п рофиля составлял: у женщин — 50 с (38,3–58,7), у му жчин 50 (42–71,2) vs 51 (42–59), p = 0,1210/53 ( 42–74,8 ), p = 0,1975 в контрольной группе . CFT у таких пациентов составлял : у женщин — 72 ( 32–92,4 м жчин – 80 с (50,2–128,7) vs 78 (62–100), p = 0,0128 80 (59–124,4), p = 0,9384 в контрол ьной группе . MCF у больных онкологического п составлял: у женщин — 70 мм (59,9–82,5), у мужчин — 63 мм (56–73,7) vs 69 мм (59–95,8), p = 0,9911 / 69 мм (53,6–90), p = 0,0135 в контрол ьной группе. У женщинпоказатели вязкости крови MaxVel были выше, чем у му жчин . Показатели MaxVel повышены у таких пациентов : у женщин — 19 мм/100 с (14,3–49,5) у му жчин — 18 мм/100 (11–27 ) vs 15 мм / 100 (11,8–22), p < 0,001 / 13 мм / 100 с (10–21,8), p <0,001 в контрол ьной группе. ь t-MaxVel понижен у больных онкологического профиля: у женщин – 65 с (48,6–112,8) , у мужчин – 81 с (50,1–135,9) vs 115 с (56,8–166), p < 0,001 / 115 с (59,8–180,8), p = 0,0002 в контрольной группе. Показатель AUC у повышен у женщин — 6451 мм 100 (5511–8148), у мужчин — 5984 мм 100 (5119–6899) vs 5778 мм 100 (4998–6655), p < 0,001 / 5662 мм 100 (4704–6385), p = 0.0105. Выводы в отличие от других мето дов, измеря ющих вариации отдельных комп онентов системы крови, метод тромбо эластографии отражает текущийп рофиль образования сгу сткав режиме реаль ного времени является информативным споссобом оценки состояния гемостаза у онкологических больных. 2007 Article Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer / M.L. Papa, F. Capasso, L. Pudore, S. Torre, S. Mango, V. Russo, P. Delrio, R. Palaia, F. Ruffolo, M.D. d’Eufemia, D. De Lucia, M. Napolitano, P. Di Micco, V. Parisi // Experimental Oncology. — 2007. — Т. 29, № 2. — С. 111-115. — Бібліогр.: 26 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/138581 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України |